- ICH GCP
- Registr klinických studií v USA
- Klinická studie NCT07690865
Investigating the Effectiveness of Personalized Optimal Gamma Auditory Frequency Stimulation Intervention on Cognitive Function Enhancement
Investigating the Effectiveness of Personalized Optimal Gamma Auditory Frequency Stimulation Intervention on Cognitive Function Enhancement: An Intervention Study
Přehled studie
Postavení
Podmínky
Detailní popis
Previous studies have shown that 40-Hz gamma-band sensory stimulation can reduce Aβ and p-tau burden and improve memory performance in AD mouse models. However, findings from human studies remain inconsistent due to differences in intervention duration and stimulation protocols. Recent studies further suggest that the optimal frequency for inducing gamma-band neural entrainment varies across individuals. In addition, a pilot study conducted in our laboratory found that the optimal auditory stimulation frequency was not necessarily 40 Hz for all participants. Therefore, the present study aims to investigate the effects of optimal auditory frequency stimulation on cognitive performance and its relationship with electrophysiological changes measured by EEG.
The study will recruit 20 cognitively healthy adults. Participants who are willing to join the study will first undergo a screening session to determine whether they meet the inclusion and exclusion criteria and whether auditory stimulation can induce significant neural entrainment. Those who meet the eligibility criteria will proceed to the intervention stage.
This study will adopt a crossover design. All participants will receive two stages of auditory stimulation intervention. Prior to the intervention, participants will be randomly assigned in a 1:1 ratio to one of two experimental groups. One group will receive optimal auditory frequency stimulation during the first stage, while the other group will receive non-optimal auditory frequency stimulation (i.e., the frequency producing the weakest neural entrainment effect). Each group will include 10 participants. During the second intervention stage, the two groups will switch experimental conditions (optimal/non-optimal auditory frequency stimulation).
Each stage will last for one month, with stimulation lasts five days per week and one hour per day. After each intervention session, participants will complete an experimental log form to record adverse effects. A one-month washout period will be implemented between the two intervention stages.
EEG recordings will be conducted before and after each intervention stage, including resting-state EEG, optimal auditory stimulation EEG recordings, and cognitive tasks.
Typ studie
Zápis (Odhadovaný)
Fáze
- Nelze použít
Kontakty a umístění
Studijní kontakt
- Jméno: Chia-Hsiung Cheng, Ph.D.
- Telefonní číslo: 3854 +886-3-211800
- E-mail: ch.cheng@mail.cgu.edu.tw
Studijní místa
-
-
Guishan
-
Taoyuan, Guishan, Tchaj-wan, 33302
- Chang Gung University
-
Kontakt:
- Chia-Hsiung Cheng, Ph.D.
- Telefonní číslo: 3854 +886-3-211800
- E-mail: ch.cheng@mail.cgu.edu.tw
-
-
Kritéria účasti
Kritéria způsobilosti
Věk způsobilý ke studiu
- Dospělý
Přijímá zdravé dobrovolníky
Popis
Inclusion Criteria:
- Age between 18 to 40 years old.
- The Cognitive Abilities Screening Instrument (CASI) score is within normal ranges adjusted for age and education.
- Participants have no history of severe neurological or psychiatric disorders (such as stroke, epilepsy, depression, migraine, etc.) that could affect cognitive function.
- Participants have not used drugs that may affect cognitive function (e.g., benzodiazepines, anticholinergic medications, etc.).
- Participants with normal or corrected vision (e.g., glasses or contact lenses) to normal levels.
- Auditory stimuli induce significant neural entrainment.
- Self-reported normal hearing
Exclusion Criteria:
- Participants enrolled in any cognitive enhancement study within the past two months.
- Participants with a history of disease that could affect cognitive function (e.g., cancer, autoimmune diseases, etc.).
- Individuals with tinnitus or hyperacusis
Studijní plán
Jak je studie koncipována?
Detaily designu
- Primární účel: Výzkum zdravotnických služeb
- Přidělení: Randomizované
- Intervenční model: Crossover Assignment
- Maskování: Singl
Zbraně a zásahy
Skupina účastníků / Arm |
Intervence / Léčba |
|---|---|
|
Experimentální: Personalized optimal gamma auditory frequency stimulation
The patient receives personalized optimal gamma auditory frequency stimulation at home for 1 month, 5 days per week, and 1 hour per day.
The stimulation frequency is selected based on the frequency that produces the strongest neural entrainment.
|
Participants will receive personalized optimal gamma auditory frequency stimulation using our app downloaded in the mobile device to play the sound for 1 hour per day, 5 days a week, over 1 month.
|
|
Aktivní komparátor: Non-optimal gamma auditory frequency stimulation
The patient receives non-optimal gamma auditory frequency stimulation at home for 1 month, 5 days per week, and 1 hour per day.
The stimulation frequency is selected based on the frequency that produces the weakest neural entrainment.
|
Participants will receive non-optimal gamma auditory frequency stimulation using our app downloaded in the mobile device to play the sound for 1 hour per day, 5 days a week, over 1 month.
|
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
changes in neurophysiological function
Časové okno: Stage 1 baseline (T1), post one-month intervention of stage 1 (T2), stage 2 baseline (T3), post one-month intervention of stage 2 (T4)
|
EEG oscillation within the gamma band obtained during resting-state and the periods of optimal and non-optimal auditory stimulation will be analyzed to evaluate and compare the neurophysiological changes.
|
Stage 1 baseline (T1), post one-month intervention of stage 1 (T2), stage 2 baseline (T3), post one-month intervention of stage 2 (T4)
|
|
changes in working memory performance
Časové okno: Stage 1 baseline (T1), post one-month intervention of stage 1 (T2), stage 2 baseline (T3), post one-month intervention of stage 2 (T4)
|
Behavioral performance and electrophysiological activity will be evaluated via a working memory task.
|
Stage 1 baseline (T1), post one-month intervention of stage 1 (T2), stage 2 baseline (T3), post one-month intervention of stage 2 (T4)
|
|
changes in inhibitory control performance
Časové okno: Stage 1 baseline (T1), post one-month intervention of stage 1 (T2), stage 2 baseline (T3), post one-month intervention of stage 2 (T4)
|
Behavioral performance and electrophysiological activity will be evaluated via an inhibitory control task.
|
Stage 1 baseline (T1), post one-month intervention of stage 1 (T2), stage 2 baseline (T3), post one-month intervention of stage 2 (T4)
|
Spolupracovníci a vyšetřovatelé
Sponzor
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia (Odhadovaný)
Primární dokončení (Odhadovaný)
Dokončení studie (Odhadovaný)
Termíny zápisu do studia
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Aktuální)
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Více informací
Termíny související s touto studií
Klíčová slova
Další relevantní podmínky MeSH
Další identifikační čísla studie
- 202600632A3
Plán pro data jednotlivých účastníků (IPD)
Plánujete sdílet data jednotlivých účastníků (IPD)?
Informace o lécích a zařízeních, studijní dokumenty
Studuje lékový produkt regulovaný americkým FDA
Studuje produkt zařízení regulovaný americkým úřadem FDA
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .
Klinické studie na Alzheimerova choroba (AD)
-
Xuanwu Hospital, BeijingZatím nenabíráme
-
Rutgers, The State University of New JerseyNational Institute on Aging (NIA)NáborAlzheimerova choroba (AD) | Zdravé stárnutíSpojené státy
-
Yuan ShenShanghai Mental Health CenterZatím nenabírámeMCI-AD, rané stadium Alzheimerovy choroby
-
BitbrainZápis na pozvánkuINZERÁT | MCI-AD, rané stadium Alzheimerovy choroby | AD-MCI | Mírné kognitivní poškození (MCI) Amnestic | Alzheimerova chorobaŠpanělsko
-
Addpharma Inc.DokončenoSmíšená dyslipidémie | Studie vlivu potravy na AD-117Jižní Korea
-
Chang Gung Memorial HospitalAleddra, Inc.NáborKognitivně normální starší dospělí | EEG mozkové oscilace | Alzheimerova choroba (AD)Tchaj-wan
-
Second Affiliated Hospital, School of Medicine,...Zatím nenabírámeAlzheimerova demence | Alzheimerova choroba (AD) | MCI-AD, rané stadium Alzheimerovy chorobyČína
-
First Affiliated Hospital of Wenzhou Medical UniversityNáborEvaluating the Efficacy and Safety of Lecanemab in Alzheimer's Disease Through Multi-omics ApproachsAlzheimerova demence (AD) | MCI-AD, rané stadium Alzheimerovy choroby | Alzheimerova chorobaČína
-
JYAMS PET Research & Development LimitedNáborSubjekty s mírnou kognitivní poruchou (MCI) u AD, Alzheimerova choroba (AD) demenceČína
-
London Health Sciences Centre Research Institute...Parkwood Hospital, London, OntarioZápis na pozvánku